scholarly journals Extension of a mitral-aorta intervalvular fibrosa pseudoaneurysm into the interatrial septum resulting in the honeycomb appearance in a patient with Takayasu’s arteritis

2021 ◽  
Vol 49 (4) ◽  
pp. 340-340
Author(s):  
Ali Hosseinsabet ◽  
◽  
Alimohammad Hajizeinali ◽  
Keyword(s):  
Takayasu’S Arteritis ◽  
Interatrial Septum ◽  
Takayasu's Arteritis ◽  
Honeycomb Appearance

Histological verification of non-specific aorta-arteritis (Takayasu's arteritis) using percutaneous transluminal atherectomy

VASA ◽  
2004 ◽  
Vol 33 (4) ◽  
pp. 247-251 ◽  
Author(s):  
Zeller ◽  
Koch ◽  
Frank ◽  
Bürgelin ◽  
Schwarzwälder ◽  
...  
Keyword(s):  
Clinical Diagnosis ◽  
Axillary Artery ◽  
Takayasu’S Arteritis ◽  
Giant Cells ◽  
Interventional Therapy ◽  
Takayasu's Arteritis ◽  
New Device ◽  
First Case ◽  
Anti Inflammatory ◽  
Percutaneous Transluminal

Diagnosis of non-specific aorto-arteritis (NSAA, Takaysu's arteritis) is typically based on clinical and investigational parameters. We report here about two patients with clinically suspected diagnosis of a Takayasu's arteritis already under anti-inflammatory therapy in whom percutaneous transluminal atherectomy of subclavian and axillary artery stenoses was performed to relief the patients from symptoms – intermittent dyspraxia of the arms – and to verify the clinical diagnosis by histology. In the first case aorto-arteritis could be histologically confirmed through the analysis of plaque material including media structures excised from the subclavian and axillary arteries using a new device for atherectomy. The biopsy showed diffuse inflammation and granulomatous lesions with giant cells typically for Takayasu's disease. In the second patient, biopsy showed no acute or chronic inflammatory signs but only atherosclerotic lesions. Percutaneous transluminal atherectomy is therefore not only an interventional but also a diagnostic tool and should be used in every case of interventional therapy of suspected aorto-arteritis to make the clinical diagnosis and as a major consequence the initiation of an aggressive anti-inflammatory medical therapy more reliable.

Transluminal Catheter angioplasty of abdominal aorta in Takayasu's arteritis

1988 ◽  
Vol 29 (5) ◽  
pp. 509-513 ◽  
Author(s):  
Z. M. Gu ◽  
G. Lin ◽  
J. R. Yi ◽  
J. M. Li ◽  
J. Zhou ◽  
...  
Keyword(s):  
Abdominal Aorta ◽  
Takayasu’S Arteritis ◽  
Takayasu's Arteritis

THE DIAGNOSE AND CLINICAL POLYMORPISM FEATURES OF TAKAYASU’S ARTERITIS

2020 ◽  
Vol 21 (2) ◽  
pp. 106-111
Author(s):  
N.S. SAMSONOV ◽  
◽  
S.A. USHAKOVA ◽  
O.Y. KHALIDULLINA ◽  
E.A. BASHTAKOVA ◽  
...  
Keyword(s):  
Takayasu’S Arteritis ◽  
Takayasu's Arteritis

HADS-depression score is a mediator for illness perception and daily life impairment in Takayasu’s arteritis

2021 ◽  
Author(s):  
Simay Erdal ◽  
Banu Nalbantoğlu ◽  
Mert Berke Gür ◽  
Murathan Yıldırım ◽  
Alperen Kılıçarslan ◽  
...  
Keyword(s):  
Daily Life ◽  
Takayasu’S Arteritis ◽  
Illness Perception ◽  
Depression Score ◽  
Takayasu's Arteritis

scholarly journals Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review

2021 ◽  
Vol 13 ◽  
pp. 1759720X2110209
Author(s):  
Diana Prieto-Peña ◽  
Pilar Bernabeu ◽  
Paloma Vela ◽  
Javier Narváez ◽  
Jesús C. Fernández-López ◽  
...  
Keyword(s):  
Adverse Events ◽  
Multicenter Study ◽  
Takayasu’S Arteritis ◽  
Imaging Techniques ◽  
Takayasu's Arteritis ◽  
Prednisone Dose ◽  
Reactive Protein ◽  
Caucasian Origin ◽  
Caucasian Patients ◽  
Sparing Effect

Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu’s arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZMONO) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZCOMBO) was performed. Results: The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5–50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0–31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5–50.0) to 5.0 (0.0–5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0–14.0) months. Twenty-three (42.6%) patients were on TCZMONO and 31 (57.4%) on TCZCOMBO: MTX ( n = 28), cyclosporine A ( n = 2), azathioprine ( n = 1). Patients on TCZCOMBO were younger [38.0 (27.0–46.0) versus 45.0 (38.0–57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0–38.0) versus 6.0 (1.0–23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7–5.6) versus 1.3 (0.3–3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. Conclusion: TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.

scholarly journals Specific microbiome profile in Takayasu’s arteritis and giant cell arteritis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Anne Claire Desbois ◽  
Dragos Ciocan ◽  
David Saadoun ◽  
Gabriel Perlemuter ◽  
Patrice Cacoub
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Takayasu’S Arteritis ◽  
Takayasu's Arteritis ◽  
Close Link ◽  
Linear Discriminant ◽  
Metabolic Functions ◽  
Microbiome Profile ◽  
Healthy Donors ◽  
Effect Size Measurement

AbstractRecent studies have provided evidence of a close link between specific microbiota and inflammatory disorders. While the vessel wall microbiota has been recently described in large vessel vasculitis (LVV) and controls, the blood microbiome in these diseases has not been previously reported (LVV). We aimed to analyse the blood microbiome profile of LVV patients (Takayasu’s arteritis [TAK], giant cell arteritis [GCA]) and healthy blood donors (HD). We studied the blood samples of 13 patients with TAK (20 samples), 9 patients with GCA (11 samples) and 15 HD patients. We assessed the blood microbiome profile by sequencing the 16S rDNA blood bacterial DNA. We used linear discriminant analysis (LDA) coupled with linear discriminant effect size measurement (LEfSe) to investigate the differences in the blood microbiome profile between TAK and GCA patients. An increase in the levels of Clostridia, Cytophagia and Deltaproteobacteria and a decrease in Bacilli at the class level were found in TAK patients compared with HD patients (LDA > 2, p < 0.05). Active TAK patients had significantly lower levels of Staphylococcus compared with inactive TAK patients. Samples of GCA patients had an increased abundance of Rhodococcus and an unidentified member of the Cytophagaceae family. Microbiota of TAK compared with GCA patients was found to show higher levels of Candidatus Aquiluna and Cloacibacterium (LDA > 2; p < 0.05). Differences highlighted in the blood microbiome were also associated with a shift of bacterial predicted metabolic functions in TAK in comparison with HD. Similar results were also found in patients with active versus inactive TAK. In conclusion, patients with TAK were found to present a specific blood microbiome profile in comparison with healthy donors and GCA subjects. Significant changes in the blood microbiome profiles of TAK patients were associated with specific metabolic functions.

Sign in / Sign up

Export Citation Format

Share Document